John Flavin is a notable entrepreneur and corporate executive with a distinguished track record in building innovative companies within the healthcare sector. Known for his leadership at several biotechnology firms, he has been instrumental in developing groundbreaking therapies that address critical medical needs. His extensive experience includes not only operational oversight but also strategic vision in navigating complex regulatory landscapes. He has served on various boards, contributing insights into market trends and business strategy while fostering partnerships aimed at driving growth. Through these roles, Flavin demonstrates profound relevance to investors focused on advancements in life sciences and health technology.
John Flavin is a notable entrepreneur and corporate executive with a distinguished track record in building innovative companies within the healthcare sector. Known for his leadership at several biotechnology firms, he has been instrumental in developing groundbreaking therapies that address critical medical needs. His extensive experience includes not only operational oversight but also strategic vision in navigating complex regulatory landscapes. He has served on various boards, contributing insights into market trends and business strategy while fostering partnerships aimed at driving growth. Through these roles, Flavin demonstrates profound relevance to investors focused on advancements in life sciences and health technology.
The healthcare sector presents transformative investment opportunities fueled by rapid technological advancements. John Flavin leverages his extensive entrepreneurial and operational background to identify high-potential ventures that aim to revolutionize patient care. By focusing on companies capable of delivering innovative solutions, he adopts a proactive approach in evaluating emerging markets and technologies. This strategic mindset allows him to capitalize on industry trends while forging valuable partnerships within the life sciences ecosystem. In fostering collaboration with key stakeholders, Flavin strives for impactful outcomes that align health innovation with sustainable business growth.
The healthcare sector presents transformative investment opportunities fueled by rapid technological advancements. John Flavin leverages his extensive entrepreneurial and operational background to identify high-potential ventures that aim to revolutionize patient care. By focusing on companies capable of delivering innovative solutions, he adopts a proactive approach in evaluating emerging markets and technologies. This strategic mindset allows him to capitalize on industry trends while forging valuable partnerships within the life sciences ecosystem. In fostering collaboration with key stakeholders, Flavin strives for impactful outcomes that align health innovation with sustainable business growth.
| Trades 1201 | Longs Won 886/1201 73% | Profit Factor 13.99 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $519,787.9 |
| Average Win $160,152.64 | Best Trade (Jun 12) $11.79M | Sharpe Ratio -6.43 |
| Average Loss -$32,204.72 | Worst Trade (Jun 30) -$1.09M | Z-Score 19.98 (100%) |
| Commissions $0 | Avg. Trade Length 1y 7m 1w | Expectancy $109,700.88 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 15,152 | 13,636 | 12,121 | 10,606 | 9,091 | 7,576 | 6,061 | 4,545 | 3,030 | 1,515 |